The newly-released Public Summary Document shows the PBAC acknowledging the efficacy and strong support for the listing of Sanofi's DUPIXENT (dupilumab) for severe atopic dermatitis but also its focus on the potential mix of new and continuing patients. …
Latest Video
New Stories
-
Novartis, Monash University and Monash Health partner for heart health
May 9, 2024 - - Latest News -
New research paper highlights potential but current failings of digital health
May 8, 2024 - - Latest News -
Parliamentary inquiry recommends reforming access arrangements for lobbyists
May 8, 2024 - - Latest News -
Bristol Myers Squibb announces new country medical director for Australia and NZ
May 8, 2024 - - Latest News -
Island announces reallocation of US grant funding to support dengue fever trial
May 8, 2024 - - Latest News -
Launch of new Queensland-based research and manufacturing hub targeting precision medicines
May 8, 2024 - - Latest News -
New TGA approvals for UCB's interleukin inhibitor
May 8, 2024 - - Latest News